Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 10:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 3,411 matching trials from the live ClinicalTrials.gov search.
Conditions
Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Ivosidenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Peripheral blood draw, Bone marrow aspirate, Buccal swab
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic Leukaemia
Interventions
Blinatumomab 9ug, Blinatumomab 28 ug, Blinatumomab, Dexamethasone
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Hematologic Malignancy
Interventions
Standard of Care, Virtual Reality intervention
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Anemia, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, busulfan, fludarabine phosphate, methotrexate, tacrolimus, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
San Francisco, California
Recruiting No phase listed Observational Accepts healthy volunteers

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

NCT00001595
Conditions
Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
Interventions
Tissue specimen collection, MRI
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 70 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1997
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Acute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia
Interventions
Fludarabine, Cyclophosphamide, Total Body Irradiation, Haploidentical stem cell transplant
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 74 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Leukemia, Chronic Myeloid
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
Interventions
TST005
Drug
Lead sponsor
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Canton, Ohio • Dallas, Texas • San Antonio, Texas
Conditions
Neuroblastoma, Sarcoma
Interventions
Cabozantinib
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
18 Months to 40 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
6
States / cities
Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 3 more
Conditions
Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers
Interventions
Humanized 3F8 Bispecific Antibody, Blood draw
Biological · Other
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
1 Year to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Myelodysplastic Syndromes
Interventions
Sorafenib-Vorinostat
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Leukemia
Interventions
dasatinib, imatinib mesylate
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Resectable Dedifferentiated Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma, Soft Tissue Fibrosarcoma, Spindle Cell Sarcoma, Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Retroperitoneal Sarcoma AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Retroperitoneal Sarcoma AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage II Retroperitoneal Sarcoma AJCC v8, Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Retroperitoneal Sarcoma AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Retroperitoneal Sarcoma AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Storiform-Pleomorphic Malignant Fibrous Histiocytoma, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Undifferentiated Pleomorphic Sarcoma, Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells, Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant, Undifferentiated Spindle Cell Sarcoma
Interventions
Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab, Radiation Therapy
Procedure · Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
365
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
Conditions
Hypertension, Osteonecrosis, Osteonecrosis Due to Drug
Interventions
Intensive Antihypertensive Therapy, Conventional Antihypertensive Therapy, Symptom Survey, Semi-structured interview
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
10 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Charlotte, North Carolina • Memphis, Tennessee
Conditions
Bone Metastases, HER2-positive Breast Cancer, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Soft Tissue Metastases, Stage IV Breast Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, trastuzumab, copper Cu 64-DOTA-trastuzumab, ado-trastuzumab emtansine, laboratory biomarker analysis
Radiation · Procedure · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
Interventions
Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine, Venetoclax
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
24
States / cities
Los Angeles, California • Orange, California • New Haven, Connecticut + 18 more
Conditions
Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer
Interventions
Vigil™
Biological
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
4
States / cities
West Palm Beach, Florida • Lebanon, New Hampshire • Dallas, Texas + 1 more
Conditions
High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions
CBX-250
Drug
Lead sponsor
Crossbow Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Duarte, California • Palo Alto, California • Tampa, Florida + 7 more
Conditions
Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Testicular Germ Cell Tumor
Interventions
DNA analysis, polymerase chain reaction, flow cytometry, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Myelofibrosis, Polycythemia Vera, Thrombocythemia
Interventions
itacitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
New Orleans, Louisiana • Bethesda, Maryland • Kansas City, Missouri + 5 more
Conditions
Myeloproliferative Diseases
Interventions
Ruxolitinib, Lenalidomide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
aldesleukin, filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, etoposide, pegylated liposomal doxorubicin hydrochloride
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Baltimore, Maryland